Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $723.6852W HIGH $1,014.99
Volume
151.97 K
Value Traded
714.09 M
Short % Float
1.96%
Days to Cover
2.7
+6.09%Week
+15.12%1 Month
+23.12%3 Month
+21.16%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
119.07 B
EPS (TTM)
39.39
P/E Ratio
25.91
Ent. Value
123.32 B
Total Shares
116.59 M
Float Shares
116.52 M
Insiders
0.06%
Institutions
94.30%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MCK Catalyst Timeline
Dated clinical, regulatory and corporate events for McKesson Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for McKesson Corporation
19Total events
5Upcoming
4Tier-1 (high impact)
2026 to 2032Coverage
Upcoming catalysts 2
Event history 13
▲AcquiredCorporate
CD&R and McKesson sign definitive agreement to acquire Option Care Health for $32.05/share (~$5.8B EV)
●Runway Guidance UpdateCorporate
McKesson reaffirms fiscal year 2027 adjusted EPS guidance of $44.20 to $45.00 and long-term adjusted EPS growth of 13% to 16%
▲Partnership / LicenseCorporate
McKesson signs agreement in principle to extend pharmaceutical distribution partnership with CVS Health through June 2032
●Timing GuidancePresentation
Unveiled Wellverse as name of future standalone Medical-Surgical Solutions business
●Management ChangeCorporate
Thomas L. Rodgers retired as EVP, Chief Strategy and Business Development Officer; Ramesh Srinivasan assumed Chief Strategy Officer role
▲Corporate ApprovalCorporate
Board declares 15% increase to quarterly dividend to $0.94 per share
●Debt Royalty FinancingCorporate
Established $2.25B secured Term Loan B facility for Medical-Surgical separation
▲Partnership / LicenseCorporate
Sold ~13% minority interest in Medical-Surgical Solutions to Apollo Funds for $1.25B
▲Equity OfferingCorporate
Completed $2.5B share repurchases including $2.25B accelerated share repurchase
Past FDA Catalysts and PDUFA Decisions
How MCK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every MCK program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Fraga FranciscoOfficer (EVP, CIO and CTO) | Sell | -800.491 5,423.496 held | $995.80 | 10/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MCK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 1.1 % (-60.7 %) | 10.97 M | 12.68 K | -65.13% ( -23.68 K) |
MCK Institutional Ownership Trends
MCK Short Interest
Shares sold short, counted twice a month.
1.96%
Short % of Float
of tradable shares sold short
2.3M
Shares Sold Short
-21.2% vs prior count
2.7 Moderate
Days to Cover
trading days of normal volume to buy every short share back
864.1K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MCK ranks across every disease it competes in
Competitive Position is a premium feature
See how MCK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMCK News
-MCK
Oct 6, 2026CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health
CD&R and McKesson Corporation have signed a definitive agreement to acquire Option Care Health for $32.05 per share, totaling around $5.8 billion. This acquisition aims to enhance their service offerings in home and alternate site infusion services. The deal signifies a strategic move in the biopharma sector, reflecting confidence in the growth of infusion services.
Read more →-MCK
Oct 1, 2026▲ +5.3%on this newsshared move
McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health
McKesson Corporation has announced an agreement to extend its pharmaceutical distribution partnership with CVS Health until June 2032. This extension reinforces their long-standing relationship and highlights their commitment to supporting patient care and community health. The agreement covers distribution to various pharmacy types, including mail order and specialty pharmacies.
Read more →-MCK
Sep 23, 2026McKesson Corporation Announces Second Quarter Fiscal 2027 Earnings Release Date
McKesson Corporation has announced the release date for its second quarter fiscal 2027 earnings. The financial results will be available after market close on November 4, 2026. Following the release, a live webcast will be held at 4:30 PM ET for investors to discuss the results.
Read more →-MCK
Aug 25, 2026Investors and Entrepreneurs Agree: AI, Enterprise Demand and Investor Confidence Are Reshaping Pharma Tech, According to New McKesson Ventures Report
A new report from McKesson Ventures highlights a significant shift in the pharma tech landscape, driven by advances in AI and increasing investor confidence. Over 60% of surveyed investors express heightened interest in pharma tech, while entrepreneurs report an improved sales environment. The report indicates a trend towards usage-based pricing models and emphasizes the growing opportunities for innovation in pharmaceutical research and development.
Read more →-MCK
Aug 25, 2026McKesson Signs Agreement to Acquire Precision Medicine Group, LLC
McKesson Corporation has signed a definitive agreement to acquire Precision Medicine Group for approximately $2.25 billion. This acquisition aims to enhance McKesson's offerings in clinical research and biopharma commercialization. Post-transaction, Precision Medicine Group will be integrated into McKesson's Oncology & Multispecialty segment.
Read more →-MCK
Aug 5, 2026McKesson Reports Fiscal 2027 First Quarter Results and Raises Full Year Adjusted EPS Guidance
McKesson Corporation announced its fiscal 2027 first quarter financial results, showcasing strong performance. The company has raised its full-year adjusted EPS guidance, indicating positive growth expectations. A live webcast of the earnings conference call is scheduled for investors to discuss these results.
Read more →-MCK
Jul 22, 2026McKesson Corporation Raises Quarterly Dividend by 15% to $0.94 Per Share
McKesson Corporation has announced a 15% increase in its quarterly dividend, raising it to $0.94 per share. This increase marks the company's tenth consecutive year of dividend growth, showcasing its strong business performance and disciplined capital allocation. The dividend will be payable on October 1, 2026, to shareholders of record on September 1, 2026.
Read more →-MCK
Jul 13, 2026McKesson Releases Fiscal Year 2026 Impact Report
McKesson has released its Fiscal Year 2026 Impact Report, showcasing the company's initiatives in transforming its purpose into actionable steps within the healthcare sector. The report emphasizes McKesson's commitment to improving healthcare outcomes and corporate responsibility. This release reflects the company's ongoing efforts to make a positive impact in the industry.
Read more →-MCK
Jun 24, 2026McKesson Corporation Announces First Quarter Fiscal 2027 Earnings Release Date
McKesson Corporation has announced the date for its earnings release for the first quarter of fiscal 2027. The announcement provides investors with important information regarding the company's financial performance. Further details regarding the earnings report will likely follow closer to the release date.
Read more →-MCK
Jun 23, 2026McKesson ideaShare 2026 Fuels Momentum for Independent Pharmacies
The article discusses the McKesson ideaShare 2026 event, which aims to support independent pharmacies. It highlights the importance of collaboration and innovation in enhancing pharmacy operations. However, specific details about the event's impact or outcomes are not provided.
Read more →-MCK
Jun 2, 2026McKesson Closes Strategic Investment with Apollo Funds for Minority Interest in Medical-Surgical Solutions
McKesson has finalized a strategic investment with Apollo Funds, acquiring a minority interest in its Medical-Surgical Solutions segment. This move is part of McKesson's strategy to enhance its offerings in the medical-surgical market. The investment is expected to strengthen McKesson's position in the healthcare supply chain.
Read more →-MCK
May 7, 2026McKesson Corporation Reports Fiscal 2026 Fourth Quarter Results
McKesson Corporation reported strong financial results for the fourth quarter and fiscal year 2026, with revenues of $96.3 billion and a 6% increase year-over-year. Adjusted earnings per diluted share rose 16%, exceeding long-term growth targets. The company also announced a significant share repurchase program and plans to focus on high-growth areas in oncology and biopharma services.
Read more →-MCK
May 7, 2026McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Results, Provides Fiscal 2027 Guidance, and Reaffirms Long-Term Financial Growth Targets
McKesson has reported its financial results for the fourth quarter and full year of fiscal 2026. The company also provided guidance for fiscal 2027 and reaffirmed its long-term financial growth targets. The report indicates a stable outlook for the company moving forward.
Read more →-MCK
Apr 22, 2026McKesson Corporation Declares Quarterly Dividend
McKesson Corporation's Board of Directors has declared a quarterly dividend of 82 cents per share, payable on July 1, 2026. Shareholders of record as of June 1, 2026, will receive this dividend. This announcement highlights McKesson's ongoing commitment to shareholder value and financial health.
Read more →-MCK
Apr 20, 2026McKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutions
McKesson has signed an agreement with Apollo Funds to secure a strategic minority interest in its Medical-Surgical Solutions division. This partnership aims to enhance McKesson's capabilities in the medical-surgical market. Further details about the financial implications or strategic goals of this agreement were not disclosed in the announcement.
Read more →-MCK
Mar 6, 2026MCKESSON CORPORATION ANNOUNCES FOURTH QUARTER FISCAL 2026
McKesson Corporation has announced that it will release its fourth quarter fiscal 2026 financial results after the market closes on May 7, 2026. CEO Brian Tyler and CFO Britt Vitalone will host a live webcast to discuss these results. Vitalone is also scheduled to participate in several upcoming healthcare conferences, indicating McKesson's active involvement in the industry. Furthermore, the company has reaffirmed its full-year outlook for fiscal 2026, reflecting confidence in its financial performance.
Read more →-MCK
Mar 5, 2026McKesson Announces Planned CFO Transition
McKesson Corporation announced the retirement of CFO Britt Vitalone after 20 years, with Kenny Cheung set to succeed him on May 29, 2026. Vitalone will remain as a strategic advisor during the transition. The company continues to perform well, reporting record revenue and profits, signaling strong momentum in its business operations.
Read more →-MCK
Mar 5, 2026McKesson Announces Planned CFO Transition Britt Vitalone announces retirement, Kenny Cheung named as successor
McKesson Corporation announced the retirement of CFO Britt Vitalone after a commendable 20-year tenure, with Kenny Cheung set to succeed him effective May 29, 2026. Vitalone will remain with the company as a strategic advisor, supporting a smooth leadership transition and the planned separation of McKesson's Medical Surgical Solutions segment. The leadership change occurs as McKesson continues to achieve strong financial performance, reporting record revenue and operating profits in its recent earnings announcement.
Read more →-MCK
Feb 5, 2026▲ +16.5%on this news
McKesson Corporation Reports Fiscal 2026 Third Quarter Results and Raises Full Year Adjusted EPS Guidance
McKesson Corporation has announced its fiscal 2026 third quarter financial results, showcasing a strong performance. The company has also raised its full-year adjusted EPS guidance, indicating confidence in its financial trajectory. A live webcast of the earnings conference call will be held for investors to discuss these results.
Read more →-MCK
Feb 4, 2026McKESSON CORPORATION REPORTS FISCAL 2026 THIRD QUARTER RESULTS AND RAISES FULL YEAR ADJUSTED EPS GUIDANCE
McKesson Corporation reported strong financial results for the third quarter of fiscal 2026, with quarterly revenues of $106.2 billion, representing an 11% increase. The company raised its adjusted earnings per diluted share guidance to between $38.80 and $39.20, indicating a projected growth of 17% to 19% compared to the previous year. Key drivers of revenue growth included increased prescription volumes from retail clients and performance improvements in its oncology and multispecialty platforms. Additionally, McKesson successfully divested its Norwegian retail operations, reinforcing its strategic focus on sustainable growth and core distribution businesses.
Read more →About McKesson Corporation
Headquarters6555 STATE HIGHWAY 161, IRVING, TX, 75039
BIOPHARMAWATCH ELITE PLUS
Trade the next MCK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime